AwardedSpainGoodsFramework agreement€85,680
Suministro de medicamentos con principio activo Factor VIII de la coagulacion recombinante.
- Published
- Published 20 July 2026
Overview
The Servicio Murciano de Salud has awarded a contract for the supply of recombinant factor VIII coagulation medications derived from a framework agreement with Ingesa. The contract, awarded on 2 July 2026 for a total value of 9,441,858.05 EUR, was divided among five suppliers: Bayer Hispania, Novo Nordisk Pharma, Pfizer, Swedish Orphan Biovitrum (SOBI), and Takeda Farmacéutica España.
Key details
- Country
- Spain
- Status
- Awarded
- Category
- Goods
- Estimated value
- €85,680
- Procedure
- Direct
- Contract type
- Framework agreement
- Published
- 20 July 2026
Medicinal products for the blood, blood-forming organs and the cardiovascular systemMedicinal products for the blood and blood-forming organs
Award outcome
- Awarded value
- €9,441,858
- Award date
- 2 July 2026
- BAYER HISPANIA, S.L.
- NOVO NORDISK PHARMA, S.A.
- PFIZER, S.L.
- SWEDISH ORPHAN BIOVITRUM, S.L. (SOBI)
- TAKEDA FARMACÉUTICA ESPAÑA, S.A.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
20 July 2026
Contracting authority
Servicio Murciano de Salud - Junta de Compras
Procuring entityEspinardo, Spain
ID_PLATAFORMA: 41261690169929
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.